Spots Global Cancer Trial Database for Safety of Effivia®, a Bevacizumab Biosimilar
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Safety of Effivia®, a Bevacizumab Biosimilar
Official Title: Post-marketing Safety of Effivia®, a Bevacizumab Biosimilar: Phase IV, Observational, Multicenter Clinical Study in Mexican Population
Study ID: NCT06313268
Interventions
Study Description
Brief Summary: This is a post-marketing observational study aimed to evaluated the safety profile of Effivia®, a biosimilar of bevacizumab, in mexican patients with different types of cancer.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UMAE Hospital de Especialidades No. 1, León, Guanajuato, Mexico
Hospital de Gineco-Obstetricia No. 3, Azcapotzalco, Mexico City, Mexico
Hospital de Oncología, UMAE Centro Médico Nacional Siglo XXI, Cuauhtémoc, Mexico City, Mexico
Instituto Nacional de Cancerología, Tlalpan, Mexico City, Mexico
Hospital de Oncología IMSS Puebla, Puebla, , Mexico
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
